G Cervetti1, S Galimberti2, E Sordi2, G Buda2, E Orciuolo2, N Cecconi2, M Petrini2. 1. Section of Hematology, Department of Oncology, Transplants and Advances in Medicine, University of Pisa, Pisa, Italy. Electronic address: juliacervetti@alice.it. 2. Section of Hematology, Department of Oncology, Transplants and Advances in Medicine, University of Pisa, Pisa, Italy.
Abstract
BACKGROUND: Splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes is an indolent lymphoma that typically affects elderly patients. Treatment is required in symptomatic cases. Splenectomy remains one of the first-line options in patients fit for surgery. The best therapeutic strategy has not yet been identified. Among different possible chemotherapeutic approaches, purine analogues, alone or in association with rituximab, seem to be a valid therapeutic choice. PATIENTS AND METHODS: Fifty SMZL patients were treated with cladribine with or without anti-CD20 mAb. RESULTS: Forty-six of 50 patients were assessable for response. Overall response rate was 87%: 24 of 46 patients (52%) achieved a complete hematological response (CR), 16 of 46 (35%) a partial response and 6 (13%) were unresponsive. Interestingly, 15 of 24 cases (62%) in CR also achieved a molecular remission. CONCLUSIONS: The present results indicate that this schedule is a valid therapeutic approach in SMZL. Addition of rituximab significantly improved quality of response and consequently the outcome of the disease.
BACKGROUND:Splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes is an indolent lymphoma that typically affects elderly patients. Treatment is required in symptomatic cases. Splenectomy remains one of the first-line options in patients fit for surgery. The best therapeutic strategy has not yet been identified. Among different possible chemotherapeutic approaches, purine analogues, alone or in association with rituximab, seem to be a valid therapeutic choice. PATIENTS AND METHODS: Fifty SMZL patients were treated with cladribine with or without anti-CD20 mAb. RESULTS: Forty-six of 50 patients were assessable for response. Overall response rate was 87%: 24 of 46 patients (52%) achieved a complete hematological response (CR), 16 of 46 (35%) a partial response and 6 (13%) were unresponsive. Interestingly, 15 of 24 cases (62%) in CR also achieved a molecular remission. CONCLUSIONS: The present results indicate that this schedule is a valid therapeutic approach in SMZL. Addition of rituximab significantly improved quality of response and consequently the outcome of the disease.
Authors: Ariela Noy; Sven de Vos; Catherine Thieblemont; Peter Martin; Christopher R Flowers; Franck Morschhauser; Graham P Collins; Shuo Ma; Morton Coleman; Shachar Peles; Stephen Smith; Jacqueline C Barrientos; Alina Smith; Brian Munneke; Isaiah Dimery; Darrin M Beaupre; Robert Chen Journal: Blood Date: 2017-02-06 Impact factor: 22.113
Authors: Christina Kalpadakis; Gerassimos A Pangalis; Maria K Angelopoulou; Sotirios Sachanas; Flora N Kontopidou; Xanthi Yiakoumis; Stella I Kokoris; Evagelia M Dimitriadou; Maria N Dimopoulou; Maria Moschogiannis; Penelope Korkolopoulou; Marie-Christine Kyrtsonis; Marina P Siakantaris; Theodora Papadaki; Panayiotis Tsaftaridis; Eleni Plata; Helen E Papadaki; Theodoros P Vassilakopoulos Journal: Oncologist Date: 2013-01-23
Authors: Marlene Troch; Barbara Kiesewetter; Wolfgang Willenbacher; Ella Willenbacher; Armin Zebisch; Werner Linkesch; Michael Fridrik; Leonhard Müllauer; Richard Greil; Markus Raderer Journal: Haematologica Date: 2012-09-14 Impact factor: 9.941
Authors: E Broussalis; J Kraus; A B Kunz; G Luthringshausen; M McCoy; W Muss; G Hutarew; G Ladurner; E Trinka; M Killer-Oberpfalzer Journal: Case Rep Neurol Date: 2011-05-31
Authors: Giovanni Carulli; Alessandra Marini; Eugenio M Ciancia; Joseph Bruno; Silvana Vignati; Paola Lambelet; Elisa Cannizzo; Virginia Ottaviano; Sara Galimberti; Francesco Caracciolo; Maria I Ferreri; Elena Ciabatti; Mario Petrini Journal: J Med Case Rep Date: 2011-09-23
Authors: Ariela Noy; Sven de Vos; Morton Coleman; Peter Martin; Christopher R Flowers; Catherine Thieblemont; Franck Morschhauser; Graham P Collins; Shuo Ma; Shachar Peles; Stephen D Smith; Jacqueline C Barrientos; Elizabeth Chong; Shiquan Wu; Leo W-K Cheung; Kevin Kwei; Bernhard Hauns; Israel Arango-Hisijara; Robert Chen Journal: Blood Adv Date: 2020-11-24